# RAS Program at FNL

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2024 · $1,009,826

## Abstract

The RAS Program is a targeted plan to develop therapeutic strategies against cancers driven by abnormal RAS signaling, especially as a consequence of RAS gene mutations, under the auspices of the Frederick National Laboratory for Cancer Research (FNLCR), the only Federally Funded Research and Development Center (FFRDC) in the Department of Health and Human Services. It is envisioned that the program will be a hub and spoke model, with scientific leaders, core facilities and important technologies at the FNLCR hub, and research led by investigators at companies, academic institutions and the NCI intramural research program at the spokes. There are five projects currently under development in FY14 to target these cancers. This expenditure is for the purpose of capital equipment to carry out laboratory research at FNLCR.

## Key facts

- **NIH application ID:** 11053278
- **Project number:** 75N91019D00024-P00035-759102000003-22
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LEONARD FREEDMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,009,826
- **Award type:** —
- **Project period:** 2020-08-31 → 2024-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11053278

## Citation

> US National Institutes of Health, RePORTER application 11053278, RAS Program at FNL (75N91019D00024-P00035-759102000003-22). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11053278. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*